Stock · NATCOPHARM · Healthcare
NATCOPHARM share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for NATCO PHARMA LIMITED, refreshed every end-of-day run. A systematic, data-only read on NATCO PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads NATCOPHARM as two-way with a Crack Score of 61/100 as of 25 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 24 Jul 2026
Where NATCOPHARM stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
100/100Fundamental axis
83/100Money flow
48/100Result pulse · Q4 FY26
33/100Technical evidence
price below 50DMA
price below 150DMA
price below 200DMA
200DMA falling
downtrend frame (50 < 200 DMA)
50DMA falling
rally testing a falling MA
RSI 42.1 (relief rally zone)
Red flags
below 200DMA (not a long-side trend)
profit collapse (-33.74% YoY)
weak filed result (score 33.0)
Relative valuation
P/E (TTM)
11.6P/E vs sector
+0.2%Sector percentile
0PEG
n/aScanner levels from the deterministic engine run of 2026-07-24, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 25 Jul 2026
Support and resistance for NATCOPHARM are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the NATCOPHARM chart, refreshed every end-of-day run.
The Crack Score, and how it is built61 / 100 · Constructive
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for NATCOPHARM, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on NATCOPHARM reads right now.
The editorial price read on NATCOPHARM is mixed. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on NATCOPHARM can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving NATCOPHARM.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why NATCOPHARM moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
NATCO PHARMA LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
33 / 100Revenue
Rs 739 crNet profit
Rs 269 crEPS (quarter)
Rs 14.96| Growth | YoY | QoQ |
|---|---|---|
| Revenue | -39.5% | +14.2% |
| Net profit | -33.7% | +77.8% |
| Net margin | +36.4% | |
Figures are the Q4 FY26 result for NATCO PHARMA LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter32 quarters on record
NATCO PHARMA LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
NATCOPHARM official result trail
32 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 739 cr | Rs 14.96 | -33.7% | 33/100 | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 647 cr | Rs 8.46 | n/a | n/a | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 1,363 cr | Rs 28.94 | n/a | n/a | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 1,329 cr | Rs 26.84 | n/a | 58/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 1,221 cr | Rs 22.70 | n/a | n/a | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 475 cr | Rs 7.43 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 1,371 cr | Rs 37.81 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 1,363 cr | Rs 37.32 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 1,068 cr | Rs 21.56 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 759 cr | Rs 11.88 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 1,031 cr | Rs 20.60 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 1,141 cr | Rs 23.26 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 898 cr | Rs 15.11 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 493 cr | Rs 3.41 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 432 cr | Rs 3.11 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 885 cr | Rs 17.55 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 597 cr | Rs -2.77 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 561 cr | Rs 4.41 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 377 cr | Rs 3.57 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 410 cr | Rs 4.11 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 331 cr | Rs 2.91 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 355 cr | Rs 3.44 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 802 cr | Rs 11.12 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 563 cr | Rs 6.74 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 455 cr | Rs 5.17 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 482 cr | Rs 5.75 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Consolidated, audited | Rs 486 cr | Rs 6.55 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 492 cr | Rs 7.87 | n/a | n/a | Filing |
| Q4 FY19ended 31 Mar 2019 / Consolidated, audited | Rs 456 cr | Rs 6.59 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Consolidated, audited | Rs 557 cr | Rs 8.65 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Consolidated, audited | Rs 544 cr | Rs 9.89 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Consolidated, audited | Rs 539 cr | Rs 9.84 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
NATCO PHARMA LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
4,078 crNet profit (TTM)
1,419 crEBIT (TTM)
1,528 crProfit before tax (TTM)
1,491 crNet margin (TTM)
34.8%Finance costs (TTM)
36.7 crBalance sheet, as filed 2026-03-31
Total assets
11,074 crShareholder equity
9,221 crTotal borrowings
706 crCash and equivalents
199 crInventory
909 crTrade receivables
881 crThe cash engine, latest filed year
Operating cash flow
1,768 crCapex
391 crFree cash flow
1,377 crInvesting flow
-2,143 crFinancing flow
298 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 4,078 cr | 1,419 cr | 9,221 cr | 706 cr | 1,768 cr |
| FY25 | 4,430 cr | 1,883 cr | 7,612 cr | 273 cr | 1,697 cr |
| FY24 | 3,999 cr | 1,388 cr | 5,853 cr | 363 cr | 1,212 cr |
| FY23 | 2,707 cr | 715 cr | 4,874 cr | 165 cr | 849 cr |
| FY22 | 1,945 cr | 170 cr | 4,264 cr | 404 cr | 46.5 cr |
| FY21 | 2,052 cr | 442 cr | 4,123 cr | 268 cr | n/a |
Every figure is parsed from NATCO PHARMA LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record18 earnings calls
Every NATCOPHARM earnings call BazaarBaazi has indexed, latest 30 Jun 2026. Read management in its own words, straight from the filed transcript.
NATCO PHARMA LIMITED earnings calls on record
18 calls since 30 Jun 2022
Show 10 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed1 disclosure
Every recent official filing from NATCO PHARMA LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
NATCO PHARMA LIMITED's most recent official filing is a Earnings dated 31 Mar 2026.
Event Heat
41 / 100Event Heat is a dated net read of NATCO PHARMA LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the NATCOPHARM chart. Not a substitute for a registered research note.
| Ticker | NATCOPHARM |
|---|---|
| Full name | NATCO PHARMA LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE987B01026 |
| Market-cap band | ~17,296 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | NATCOPHARM |
Reference chartLevels in show
The daily frame the desk reads on NATCOPHARM.
FAQ11 reader questions · AEO-eligible
The line on NATCOPHARM, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the NATCOPHARM share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on NATCOPHARM. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for NATCOPHARM?
The BazaarBaazi Crack Score for NATCOPHARM is 61 out of 100 as of 25 Jul 2026, a constructive reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on NATCOPHARM?
Strike-level option inventory for NATCOPHARM is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is NATCOPHARM in and which peers does BazaarBaazi track?
NATCOPHARM sits in Healthcare (mid cap), indicative market cap ~17,296 cr (indicative), ISIN INE987B01026. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on NATCO PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the NATCOPHARM view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on NATCOPHARM is mixed, published in Systematic Read on 21 Jul 2026.
Is NATCOPHARM a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-24 run of the 500-name BazaarBaazi setup scanner, NATCO PHARMA LIMITED sits in the Scanned tier with a setup score of 82/100 (technical 100, fundamental 83). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read NATCO PHARMA LIMITED's earnings call transcripts?
BazaarBaazi indexes 18 NATCOPHARM earnings calls going back to 2022-06-30, latest 2026-06-30. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was NATCO PHARMA LIMITED's Q4 FY26 net profit?
NATCO PHARMA LIMITED reported a net profit of Rs 269 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -33.7% year on year. The figure is from the company's official NSE filing.
What was NATCO PHARMA LIMITED's Q4 FY26 revenue?
NATCO PHARMA LIMITED reported revenue of Rs 739 cr for Q4 FY26. That is -39.5% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate NATCO PHARMA LIMITED's Q4 FY26 result?
BazaarBaazi gives NATCO PHARMA LIMITED's Q4 FY26 result a Result Pulse of 33 out of 100, with a verdict of Weak. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Natco Pharma Ltd announced recently?
The most recent official filing on record for Natco Pharma Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside NATCOPHARM, each a living view refreshed every end-of-day run.